In a phase 3 study, telikibart achieved EASI-75 in 69.6% of adult patients with atopic dermatitis at Week 16, with rates above 94% by Week 52.
Opinion|Videos|November 11, 2024
Screening and Prevention for CKD
Key Takeaways
- Identifying at-risk patients for CKD in Type 2 Diabetes involves assessing hypertension, family history, and blood glucose levels.
- Screening tests for CKD include eGFR and UACR, essential for early detection in diabetic patients.
Panelists discuss the criteria for identifying at-risk patients for chronic kidney disease (CKD) testing in type 2 diabetes and review the screening and detection tests, emphasizing the critical importance of early detection through blood and urine tests for both CKD management and heart failure prevention.
Advertisement
- What criteria should be used to identify at-risk patients for CKD testing in Type 2 Diabetes?
- Can you review the screening and detection tests for CKD used in patients with diabetes patients?
- Why is early detection of CKD through blood and urine tests so important? Why is it important from the perspective of heart failure?
Advertisement
Related to this article
Ryaltris pediatric approval, lonvo-z and deucrictibant HAE filings, PVX108 Fast Track, and Palforzia's exit headline Q3 2026 allergy news.
An indirect comparison finds higher placebo-adjusted skin and itch responses with upadacitinib vs nemolizumab in atopic dermatitis.
Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.
Check out highlights from news published on Day 3 of the EADV Congress 2026, spanning psoriasis, cutaneous lupus, atopic dermatitis, and more.
Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 30 days.
Werth discusses what the 52-week AMETHYST Part A data add to the case for litifilimab in antimalarial-refractory cutaneous lupus erythematosus.
Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.
Advertisement
Advertisement
Trending on HCPLive
1
Phase 3 Ritlecitinib Results in Vitiligo, With Iltefat Hamzavi, MD
2
EADV Congress 2026: Day 3 Recap—5 Headlines to Know
3
The Liver Keeps the Score: Americans Are Drinking Less, but Alcohol-Associated Liver Disease May Lag
4
AMETHYST: Litifilimab Sustains CLE Gains at 52 Weeks, With Victoria Werth, MD
5